Based out of Amsterdam,  Avidicure, a biotechnology company, announced its launch with $50M (approximately €43.8M) in a seed financing round led by EQT Life ...

Many patent applicants currently face difficulty in obtaining antibody claims because of written description and enablement ...

Synthetic Design Lab Inc., which emerged from stealth with a $20 million seed round and a platform technology aimed at advancing the antibody-drug conjugate (ADC) space, began with its founders ...

A team of scientists has uncovered the remarkable potential of a human antibody, mAb 3A6, in fighting Ebola virus infections.

Synthetic Design Lab, a next-generation antibody-drug conjugate (ADC) company advancing its novel SYNTHBODY therapeutic ...

Market turmoil may have frozen the traditional IPO pipeline, but German antibody biotech Veraxa is turning to the special purpose acquisition company (SPAC) model to hop onto the Nasdaq. | Market ...

The proposed transaction values VERAXA Biotech AG at USD 1.64 billion with expected gross cash proceeds up to USD 253 million held in trust by Voyager Acquisition Corp.

GenAI offers a realistic path forward in tackling previously undruggable targets, with the potential to reshape the entire ...

AP402 targets p95HER2, a truncated form of HER2 present in 30-40% of HER2-positive cancers, which is associated with exceptionally poor prognosis, and not addressable by conventional anti-HER2 ...

BigHat Biosciences, a biotechnology company, has entered a strategic collaboration with Eli Lilly and Company.